Angimmune welcomes inquiries on the licensing of its technology. Our first candidate Resimmune, is entering a pivotal Phase II trial (two-arm with an active comparator) for the treatment of Cutaneous T-Cell Lymphoma (CTCL). This trial is designed to support Fast Track Designation as well as a Marketing Application. Protocols are being developed to test Resimmune in the treatment of Aplastic anemia and the treatment of Multiple sclerosis. Resimmune is also in a Phase I/II trial to test the hypothesis that Resimmune can act as an immunomodulator of late stage metastatic melanoma when combined with palliative radiation to induce the priming of activated T cells with tumor antigens.
Orphan Drug Designation
Resimmune® or A-dmDT390-bisFv(UCHT1) has been granted Orphan Drug Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL).
Because a wide variety of antibody sequences can be used in the DT390/Pichia Platform, collaborations with other companies having proprietary antibodies may be mutually beneficial. Angimmune holds exclusive licenses from NIH of all intellectual property developed by Neville, Woo, and Liu.
Licensing inquiries – US and worldwide
Email: Paul Neville
Director of Operations